Jaguar Health’s Napo submitted the IND for NP-300 for the symptomatic treatment & relief from infectious diarrhea from pathogens. The company has also received partial financial support for IND enabling preclinical toxicity studies by the NIAID
The company intends to receive a TDPRV for the development of NP-300 for the same indication. Jaguar entered into a $6M financing agreement with Streeterville Capital, under which Streeterville received the right to 18% of the gross proceeds from the sale of TDPRV
Jaguar expects to initiate the P-I clinical trial evaluating NP-300 for the treatment of cholera-related diarrhea by Sep 30, 2022. NP-300 is an oral botanical drug sustainably derived from the Croton lechleri tree
Ref: Accesswire | Image: Jaguar Health
